반응식
[NH2:1][C:2]1[CH:23]=[CH:22][C:5]2[N:6]([C:10]3[S:11][C:12]4[C:13](=[O:21])[NH:14][C:15]([CH3:20])([CH3:19])[CH2:16][C:17]=4[N:18]=3)[CH2:7][CH2:8][O:9][C:4]=2[CH:3]=1.F[P-](F)(F)(F)(F)F.N1(OC(N(C)C)=[N+](C)C)C2C=CC=CC=2N=N1.Cl.[CH3:49][N:50]1[CH2:55][CH2:54][CH:53]([C:56](O)=[O:57])[CH2:52][CH2:51]1.CCN(C(C)C)C(C)C>CN(C=O)C.O.CC#N>[CH3:19][C:15]1([CH3:20])[NH:14][C:13](=[O:21])[C:12]2[S:11][C:10]([N:6]3[C:5]4[CH:22]=[CH:23][C:2]([NH:1][C:56]([CH:53]5[CH2:54][CH2:55][N:50]([CH3:49])[CH2:51][CH2:52]5)=[O:57])=[CH:3][C:4]=4[O:9][CH2:8][CH2:7]3)=[N:18][C:17]=2[CH2:16]1참가 물질
반응물 4
생성물 1
시약·촉매·용매 3
실험 절차
To a stirred solution of Example 233 (0.049 g, 0.15 mmol), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.111 g, 0.29 mmol) and 1-methylpiperidine-4-carboxylic acid hydrochloride (0.034 g, 0.19 mmol) in DMF (0.5 mL) was added DIPEA (0.06 mL, 0.35 mmol). The reaction mixture was stirred at r.t. for 16 h. MeCN (1 mL) and water (1 mL) were added. The insoluble material was filtered, and the filtrate concentrated in vacuo. Purification by preparative HPLC (Method 6) gave the title compound (0.035 g, 51%) as a yellow solid. δH (CD3OD) 7.91 (1H, d, J 9.0 Hz), 7.37 (1H, d, J 2.3 Hz), 7.11 (1H, dd, J 8.9 and 2.3 Hz), 4.40-4.30 (2H, m), 4.20-4.09 (2H, m), 3.62 (2H, d, J 12.6 Hz), 3.17-3.02 (2H, m), 2.92 (3H, s), 2.89 (2H, s), 2.76-2.60 (1H, m), 2.34-1.91 (4H, m), 1.39 (6H, s). Exchangeable protons were not observed. LCMS (ES+) 456.21 (M+H)+, RT 1.80 minutes (Method 1).
후처리
- filtrationThe insoluble material was filtered
- concentrationthe filtrate concentrated in vacuo
- customPurification by preparative HPLC (Method 6)
출처 및 근거
- ORD 기록
- ord-fcbfc1827857424ba3909b4ecdeac4af
- 출처 데이터셋
- uspto-grants-2012_08
- 특허 번호
- US08242116B2
연결된 노트
불러오는 중…